Dorothy M K Keefe

Summary

Affiliation: South Australia
Country: Australia

Publications

  1. ncbi Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis
    Zhi Yi Ong
    School of Medicine, University of Adelaide, Adelaide, South Australia
    Radiat Oncol 5:22. 2010
  2. ncbi Sucrose breath testing and intestinal mucositis
    Dorothy M K Keefe
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
    Cancer Biol Ther 5:1196-8. 2006
  3. ncbi Updated clinical practice guidelines for the prevention and treatment of mucositis
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
    Cancer 109:820-31. 2007
  4. ncbi The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem!
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital and Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South, Australia
    Cancer Biol Ther 5:1282-4. 2006
  5. ncbi Intestinal mucositis: mechanisms and management
    Dorothy M Keefe
    Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia
    Curr Opin Oncol 19:323-7. 2007
  6. ncbi Mucosal injury from targeted anti-cancer therapy
    Dorothy M K Keefe
    Department of Medical Oncology, Royal Adelaide Hospital and Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, North Terrace, Adelaide, Australia
    Support Care Cancer 15:483-90. 2007
  7. ncbi Supportive care silos: time to forge cross-links, using mucositis as an example
    Dorothy M K Keefe
    RAH Cancer Centre and Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, South Australia, Australia
    Curr Opin Support Palliat Care 1:40-2. 2007
  8. ncbi Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care
    Dorothy Keefe
    Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
    Curr Opin Support Palliat Care 2:19-21. 2008
  9. ncbi Emerging drugs for chemotherapy-induced mucositis
    Dorothy M Keefe
    Royal Adelaide Hospital, RAH Cancer Centre, North Terrace, Adelaide, SA 5000, Australia
    Expert Opin Emerg Drugs 13:511-22. 2008
  10. ncbi Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review
    Dorothy Keefe
    Discipline of Medicine, School of Medicine, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia
    Oncologist 16:432-44. 2011

Detail Information

Publications50

  1. ncbi Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis
    Zhi Yi Ong
    School of Medicine, University of Adelaide, Adelaide, South Australia
    Radiat Oncol 5:22. 2010
    ..Therefore, the aim of the present study was to characterise the expression of pro-inflammatory cytokines in the gastrointestinal tract using a rat model of fractionated radiotherapy-induced toxicity...
  2. ncbi Sucrose breath testing and intestinal mucositis
    Dorothy M K Keefe
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
    Cancer Biol Ther 5:1196-8. 2006
  3. ncbi Updated clinical practice guidelines for the prevention and treatment of mucositis
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
    Cancer 109:820-31. 2007
    ..These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients. Cancer 2007;109:820-31. (c) 2007 American Cancer Society...
  4. ncbi The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem!
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital and Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South, Australia
    Cancer Biol Ther 5:1282-4. 2006
  5. ncbi Intestinal mucositis: mechanisms and management
    Dorothy M Keefe
    Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia
    Curr Opin Oncol 19:323-7. 2007
    ..To describe the advances in the rapidly evolving field of intestinal (or alimentary) mucositis during the past year...
  6. ncbi Mucosal injury from targeted anti-cancer therapy
    Dorothy M K Keefe
    Department of Medical Oncology, Royal Adelaide Hospital and Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, North Terrace, Adelaide, Australia
    Support Care Cancer 15:483-90. 2007
    ..Whilst we increasingly understand the mechanisms underlying the toxicities of chemotherapy and radiotherapy, the addition of targeted treatments requires a new understanding of both toxicity and interacting mechanisms...
  7. ncbi Supportive care silos: time to forge cross-links, using mucositis as an example
    Dorothy M K Keefe
    RAH Cancer Centre and Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, South Australia, Australia
    Curr Opin Support Palliat Care 1:40-2. 2007
  8. ncbi Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care
    Dorothy Keefe
    Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
    Curr Opin Support Palliat Care 2:19-21. 2008
  9. ncbi Emerging drugs for chemotherapy-induced mucositis
    Dorothy M Keefe
    Royal Adelaide Hospital, RAH Cancer Centre, North Terrace, Adelaide, SA 5000, Australia
    Expert Opin Emerg Drugs 13:511-22. 2008
    ..The pathobiology of mucositis is complex, and agents that target mechanisms to prevent mucositis or accelerate healing are in high demand...
  10. ncbi Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review
    Dorothy Keefe
    Discipline of Medicine, School of Medicine, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia
    Oncologist 16:432-44. 2011
    ..Articles published in English before March 2010 were included, in addition to information from case reports and pharmaceutical agent package inserts...
  11. ncbi Severe mucositis: how can nutrition help?
    Dorothy M Keefe
    Royal Adelaide Hospital Cancer Centre, Royal Adelaide Hospital, South Australia
    Curr Opin Clin Nutr Metab Care 10:627-31. 2007
    ..To review the recent evidence on the effect of nutrition on the incidence and severity of mucositis following anticancer treatment...
  12. ncbi Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
    Richard M Logan
    Discipline of Oral Pathology, School of Dentistry, Faculty of Health Sciences, The University of Adelaide, North Terrace, Adelaide, SA 5005, Australia
    Cancer Chemother Pharmacol 63:239-51. 2009
    ..The aim of the present study was to determine whether the changes that occur in the AT are affected by the type of mucotoxic drug...
  13. ncbi Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis
    Richard M Logan
    Oral Pathology, School of Dentistry, Faculty of Health Sciences, The University of Adelaide, North Terrace, SA 5005, Australia
    Cancer Chemother Pharmacol 62:33-41. 2008
    ....
  14. ncbi Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment
    Andrea M Stringer
    Department of Medical Oncology, Royal Adelaide Hospital, South Australia
    J Support Oncol 5:259-67. 2007
    ....
  15. ncbi Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs
    Richard M Logan
    Oral Pathology, School of Dentistry, Faculty of Health Sciences, The University of Adelaide, South Australia, Australia
    Cancer Biol Ther 7:1139-45. 2008
    ..The aims of this study were to determine whether changes in serum levels of NFkappaB, TNF, IL-1beta and IL-6 following administration of different drugs predicted histological evidence of tissue damage...
  16. ncbi Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile
    Andrea M Stringer
    Department of Medical Oncology, Royal Adelaide Hospital, South Australia, Australia
    Int J Exp Pathol 90:489-99. 2009
    ..coli, exacerbating the toxicity of active metabolites. Accelerated mucous secretion and mucin release may also contribute to the delayed onset of diarrhoea...
  17. ncbi Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat
    Andrea M Stringer
    Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia
    Exp Biol Med (Maywood) 232:96-106. 2007
    ..These changes in flora may have systemic effects and in particular may contribute to the development of chemotherapy-induced mucositis...
  18. ncbi Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
    Andrea M Stringer
    Department of Medical Oncology, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia
    Cancer Biol Ther 7:1919-25. 2008
    ..However, the pathophysiology behind this debilitating side effect remains unclear. Irinotecan causes cholinergic and delayed onset diarrhea in patients, in which beta-glucuronidase produced by gut bacteria is thought to be involved...
  19. ncbi Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats
    Rachel J Gibson
    Department of Medical Oncology, The Ropl Adelaide Hospital, North Terrace, Adelaide 5000 South Australia, Australia
    Cancer Biol Ther 6:541-7. 2007
    ..Other dosing regimens were not as effective. This has important implications for the use of velafermin in GI mucositis in humans, and should be further studied...
  20. ncbi VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss
    Joanne M Bowen
    Department of Medical Oncology, Royal Adelaide Hospital, South Australia, Australia
    Cancer Biol Ther 6:1449-54. 2007
    ..One of the most common toxicities of cancer treatment is diarrhea. Probiotics have been shown effective at preventing diarrhea in inflammatory bowel disease and may prove useful in the oncology setting...
  21. ncbi Irinotecan-induced mucositis is associated with changes in intestinal mucins
    Andrea M Stringer
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
    Cancer Chemother Pharmacol 64:123-32. 2009
    ..Mucus production appears to be increased, which may contribute to the development of diarrhoea...
  22. ncbi Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy
    Joanne M Bowen
    Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
    Int J Cancer 121:1847-56. 2007
    ..Many of these changes are highly likely to be specifically related to the subsequent development of gastrointestinal mucositis...
  23. ncbi The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs
    Richard M Logan
    Oral Pathology, School of Dentistry, Faculty of Health Sciences, The University of Adelaide, North Terrace, Adelaide SA 5005, Australia
    Cancer Treat Rev 33:448-60. 2007
    ....
  24. ncbi Establishment of a single-dose irinotecan model of gastrointestinal mucositis
    Rachel J Gibson
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
    Chemotherapy 53:360-9. 2007
    ..The secondary aim was to determine if the presence of tumour altered the development of mucositis...
  25. ncbi Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats
    Rachel J Gibson
    Department of Medical Oncology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia
    Dig Dis Sci 47:2751-7. 2002
    ..We conclude that IL-11 attenuated mucositis by maintaining intestinal weight and morphometry. IL-11 did not prevent apoptosis, but rather induced compensatory crypt cell proliferation...
  26. ncbi Role of p53 in irinotecan-induced intestinal cell death and mucosal damage
    Joanne M Bowen
    Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide 5000, South Australia, Australia
    Anticancer Drugs 18:197-210. 2007
    ..Temporary inhibition of p53 activation does not markedly prevent intestinal cell death or mucositis following irinotecan treatment. Irinotecan may act through upregulation of proapoptotic proteins Bax and Bak to induce cell death...
  27. ncbi Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract
    Joanne M Bowen
    School of Medicine, University of Adelaide, Australia
    Toxicology 269:1-12. 2010
    ..Therapeutic targeting of key gene responses at the appropriate time point may prove to be effective for prevention of chemotherapy-induced gastrointestinal damage...
  28. ncbi A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2
    Ann S J Yeoh
    Department of Medical Oncology, Royal Adelaide Hospital, South Australia, Australia
    Mol Cancer Ther 6:2319-27. 2007
    ..Further studies investigating the molecular mechanisms underlying radiation-induced mucositis are planned to ultimately achieve anti-mucotoxic-targeted therapies...
  29. ncbi Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats
    Rachel J Gibson
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
    Int J Cancer 116:464-70. 2005
    ..This positive response warrants further investigation, particularly in humans...
  30. ncbi Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change
    Andrea M Stringer
    Department of Medical Oncology, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Eastwood, South Australia, Australia
    Curr Drug Metab 10:79-83. 2009
    ..This review will explore the potentially important relationship between intestinal microflora and the subsequent development of chemotherapy-induced mucositis...
  31. ncbi Animal models of mucositis: implications for therapy
    Joanne M Bowen
    University of Adelaide, Adelaide, South Australia
    J Support Oncol 9:161-8. 2011
    ..This review focuses on the animal models used to increase our understanding of the mechanisms of mucositis and translate new antimucotoxic agents into clinical trials...
  32. ncbi Irinotecan changes gene expression in the small intestine of the rat with breast cancer
    Joanne M Bowen
    Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, 5000, South Australia, Australia
    Cancer Chemother Pharmacol 59:337-48. 2007
    ..The aims of this study were to identify genes that are altered by irinotecan, to determine how these genes contribute to apoptosis and to identify any potential gene families and pathways that are important for mucositis development...
  33. ncbi Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy
    Richard M Logan
    Oral Pathology, School of Dentistry, The University of Adelaide, Adelaide, North Terrace, SA 5005, Australia
    Oral Oncol 43:395-401. 2007
    ....
  34. ncbi Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer
    Rachel J Gibson
    Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia
    J Gastroenterol Hepatol 18:1095-100. 2003
    ..The aim of the present study was to investigate the time-course of apoptosis and whole intestinal damage after irinotecan to further elucidate the mechanism behind the diarrhea...
  35. ncbi Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage
    Joanne M Bowen
    Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, 5000, South Australia, Australia
    Support Care Cancer 14:713-31. 2006
    ..This review will provide an overview of current research as well as identify areas where gaps in knowledge exist...
  36. ncbi Gastrointestinal mucositis
    Dorothy M K Keefe
    Department of Medical Oncology, Royal Adelaide Hospital, South Australia
    Semin Oncol Nurs 20:38-47. 2004
    ..IMPLICATIONS FOR NURSING PRACTICE: It is important to document the frequency and severity of gastrointestinal mucositis, and to alleviate symptoms wherever possible...
  37. ncbi Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies
    Rachel J Gibson
    Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
    Support Care Cancer 14:890-900. 2006
    ..Diarrhoea and constipation are common toxicities of chemotherapy, and both are poorly understood. They are manifestations of alimentary mucositis, a condition which affects the entire gastrointestinal tract...
  38. ncbi Gastrointestinal mucositis: a new biological model
    Dorothy M K Keefe
    Department of Medical Oncology, Royal Adelaide Hospital, SA 5000 Adelaide, Australia
    Support Care Cancer 12:6-9. 2004
    ....
  39. ncbi Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis
    Andrea M Stringer
    Dame Roma Mitchell Cancer Research Laboratory, Hanson Institute, Adelaide SA 5000, Australia
    Exp Biol Med (Maywood) 234:430-41. 2009
    ..These changes could result in systemic effects and, in particular, may contribute to the development of chemotherapy-induced mucositis...
  40. ncbi Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes
    Ann S J Yeoh
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
    Int J Radiat Oncol Biol Phys 63:1295-303. 2005
    ..The purpose of this study was therefore to investigate the expression of NFkappaB and Cox-2 in the irradiated colorectum and to correlate these with the associated histopathologic changes...
  41. ncbi Technological advances in mucositis research: new insights and new issues
    Rachel J Gibson
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
    Cancer Treat Rev 34:476-82. 2008
    ..In addition, some of these technologies have the potential to be implemented immediately in the field of mucositis research...
  42. ncbi The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer
    Rachel J Gibson
    Department of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
    Cancer Chemother Pharmacol 50:53-8. 2002
    ..KGF also reduced tumour size. CONCLUSIONS: We conclude that KGF had a modest effect on intestinal growth prior to chemotherapy. It did not protect the gut from mucositis, nor did it worsen morphometry. It reduced tumour size...
  43. ncbi New pathways for alimentary mucositis
    Joanne M Bowen
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
    J Oncol 2008:907892. 2008
    ..This review also discusses the currently known alimentary mucositis risk factors and the development of novel treatments. Suggestions for future research directions have been raised...
  44. ncbi Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans
    Joanne M Bowen
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia
    Pathology 37:56-62. 2005
    ..The aim of this study was to examine the effect of cytotoxic treatment on Bcl-2 protein expression in patients and rats with tumours...
  45. ncbi Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital Cancer Centre, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000, Australia
    Support Care Cancer 14:492-8. 2006
    ....
  46. ncbi Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?
    Noor Al-Dasooqi
    Department of Medicine, University of Adelaide, Adelaide, SA, Australia
    Cancer Chemother Pharmacol 64:1-9. 2009
    ..This prompts the consideration of MMPs as possibly being key mediators in mucositis development...
  47. ncbi Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat
    Noor Al-Dasooqi
    Department of Medicine, University of Adelaide, North Terrace, Adelaide, SA 5005, Australia
    Exp Biol Med (Maywood) 235:1244-56. 2010
    ..This prompts the consideration of MMPs as possible mediators of chemotherapy-induced mucositis...
  48. ncbi Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
    Noor Al-Dasooqi
    Department of Physiology, University of Adelaide, North Terrace, Adelaide, SA, Australia
    Invest New Drugs 27:173-8. 2009
    ..To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancer patients...
  49. ncbi Novel therapies
    Douglas E Peterson
    Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030-1605, USA
    Semin Oncol Nurs 20:53-8. 2004
    ..IMPLICATIONS FOR NURSING PRACTICE: The oncology nurse plays a pivotal role in assessing and managing mucositis in cancer patients...
  50. ncbi Mucositis guidelines: what have they achieved, and where to from here?
    Dorothy M K Keefe
    Support Care Cancer 14:489-91. 2006